Pharsight

Eliquis is owned by Bristol Myers Squibb.

Eliquis contains Apixaban.

Eliquis has a total of 2 drug patents out of which 0 drug patents have expired.

Eliquis was authorised for market use on 28 December, 2012.

Eliquis is available in tablet;oral dosage forms.

Eliquis can be used as prophylaxis of deep vein thrombosis and pulmonary embolism; reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); reduce the risk of recurrent deep vein thrombosis (dvt); treatment of deep vein thrombosis (dvt); reduce the risk of recurrent pulmonary embolism; prophylaxis of deep vein thrombosis (dvt); reducing the risk of stroke; prophylaxis of pulmonary embolism.

The generics of Eliquis are possible to be released after 24 February, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6967208	BRISTOL MYERS SQUIBB	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors	Nov, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945	BRISTOL MYERS SQUIBB	Apixaban formulations	Feb, 2031 (8 years from now)

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (dvt); Treatment of deep vein thrombosis (dvt); Reduce the risk of recurrent pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reducing the risk of stroke; Prophylaxis of pulmonary embolism

Dosage: TABLET;ORAL